Literature DB >> 9178173

Expression and mutations of p53 in salivary gland tumours.

V J Kärjä1, K J Syrjänen, A K Kurvinen, S M Syrjänen.   

Abstract

A series of 219 salivary gland tumours (103 carcinomas and 116 benign tumours) were analysed for p53 protein expression using immunohistochemistry, and for mutations in p53 gene using non-radioactive single strand conformation polymorphism (SSCP). p53 expression was present in 36% (42/116) of the benign tumours and in 54% (56/103) of the carcinomas. The highest prevalence of p53 expression was found in adenoid cystic carcinomas (69%), followed by mucoepidermoid carcinomas (67%). Of the benign tumours, pleomorphic adenomas showed the highest prevalence of p53 positivity (41%). In malignant tumours, expression of p53 bore no correlation to local recurrence, metastatic disease or survival of the patients. Exons 5 through 9 were analysed and four mutations were found in 20 cases of p53-immunopositive tumours and two in 20 p53-negative tumours. Each of the exons 5, 6 and 8/9 had two mutations, whereas no mutations were detected in exon 7.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178173     DOI: 10.1111/j.1600-0714.1997.tb01227.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  12 in total

Review 1.  Molecular biology of adenoid cystic carcinoma.

Authors:  Jia Liu; Chunbo Shao; Marietta L Tan; David Mu; Robert L Ferris; Patrick K Ha
Journal:  Head Neck       Date:  2011-10-17       Impact factor: 3.147

Review 2.  Recurrent salivary gland cancer.

Authors:  M Boyd Gillespie; W Greer Albergotti; David W Eisele
Journal:  Curr Treat Options Oncol       Date:  2012-03

3.  Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study.

Authors:  Saori Matsubayashi; Toshio Yoshihara
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-02-20       Impact factor: 2.503

Review 4.  Salivary mucoepidermoid carcinoma revisited.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-26       Impact factor: 2.503

5.  Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression.

Authors:  S I Chiosea; E L Barnes; S Y Lai; A M Egloff; R L Sargent; J L Hunt; R R Seethala
Journal:  Virchows Arch       Date:  2008-02-01       Impact factor: 4.064

6.  Satellite tumors surrounding primary pleomorphic adenomas of the parotid gland.

Authors:  Yorihisa Orita; Kazuo Hamaya; Kentaroh Miki; Akiko Sugaya; Misato Hirai; Kiyoko Nakai; Sohichiroh Nose; Tadashi Yoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-07       Impact factor: 2.503

7.  Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.

Authors:  Carolina Cavaliéri Gomes; Marina Gonçalves Diniz; Lissur Azevedo Orsine; Alessandra Pires Duarte; Thiago Fonseca-Silva; Brendan I Conn; Luiz De Marco; Cláudia Maria Pereira; Ricardo Santiago Gomez
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

8.  Immunohistochemical Expression of p53 in Pleomorphic Adenoma and Carcinoma Ex Pleomorphic Adenoma.

Authors:  Bassel Tarakji; Omar Kujan; Mohammad Z Nassani
Journal:  J Cancer Epidemiol       Date:  2010-12-28

9.  Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.

Authors:  Ehab S Abd-Elhamid; Mohamed H Elmalahy
Journal:  Diagn Pathol       Date:  2010-11-22       Impact factor: 2.644

10.  Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland.

Authors:  Satoshi Maruyama; Jun Cheng; Susumu Shingaki; Takashi Tamura; Shuichi Asakawa; Shinsei Minoshima; Yoshiko Shimizu; Nobuyoshi Shimizu; Takashi Saku
Journal:  BMC Cancer       Date:  2009-07-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.